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Purpose: 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] has recently been found to be involved in the development of
autoimmune diseases. This study was to investigate the expression and potential role of 1,25(OH)2D3 in the pathogenesis
of Vogt-Koyanagi-Harada (VKH) disease.
Methods: Blood samples were obtained from VKH patients and healthy individuals. Serum 1,25(OH)2D3 levels were
measured using ELISA. Peripheral blood mononuclear cells (PBMCs) or cluster of differentiation (CD) 4+ T cells were
cultured with or without 1,25(OH)2D3 in the presence of anti-CD3 and anti-CD28 for the measurement of cell proliferation
and cytokines. The cell proliferation was detected using the Cell Counting Kit. The levels of interleukin (IL)-17 and
interferon (IFN)-γ levels in the supernatants of PBMCs or CD4+ T cells were detected by ELISA.
Results: 1,25(OH)2D3 was significantly decreased in the serum of active VKH patients as compared with inactive VKH
patients and controls. It significantly inhibited PBMCs proliferation and CD4+ T cell proliferation. It was also able to
significantly inhibit the production of IL-17 and IFN-γ by both PBMCs and CD4+ T cells from VKH patients and controls.
Conclusions: These findings suggest that decreased expression of 1,25(OH)2D3 may be involved in the development of
VKH disease. 1,25(OH)2D3 may be potentially used in the treatment of this disease.
Vitamin  D  is  produced  in  the  skin  upon  exposure  to
sunlight or obtained from the diet [1-3]. Its receptor has been
found in the immune cells and parts of these cells are able to
produce  Vitamin  D3  [4-7].  1,25(OH)2D3,  the  biologically
active metabolite of Vitamin D3, has recently been shown to
have immunomodulation property beside its involvement in
the  bone  and  calcium  metabolism  [8,9].  Recent  studies
showed  that  1,25(OH)2D3  was  able  to  skew  the  T  cell
compartment into a more anti-inflammatory and regulated
state, as evidenced by inhibition of Th1 and Th17 cells and
promotion of Th2 and T reg cells [10,11]. In Vitro experiments
showed  that  1,25(OH)2D3  could  promote  both  innate  and
adaptive  immune  responses.  1,25(OH)2D3  receptor  gene
knockout mice showed a significantly higher susceptibility to
several autoimmune disease models, such as experimental
autoimmune  encephalomyelitis  [12,13],  experimental
autoimmune uveitis [14], and experimental allergic asthma
[15]. Additionally, serum level of 1,25(OH)2D3 was found to
be decreased in several human autoimmune diseases, such as
multiple  sclerosis  [16-18],  rheumatoid  arthritis  [19,20],
Behçet's disease [21], Graves disease [22], and systemic lupus
erythematosus  [23,24].  All  these  results  suggest  that
1,25(OH)2D3 is a negative factor and that down-regulated
expression  of  1,25(OH)2D3  is  possibly  involved  in  the
pathogenesis of these diseases.
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Vogt-Koyanagi-Harada  (VKH)  disease  is  an
autoimmune  disease  characterized  by  a  bilateral
granulomatous  panuveitis  and  systemic  disorders.  It
frequently results in severely decreased vision or even to
blindness if not treated appropriately [25-27]. It is one of the
most common uveitis entities in China as well as in the Far
East  of  Asia  [26,28-30].  Studies  have  showed  that  both
enhanced T helper (Th) 1 and Th17 cell responses are involved
in the pathogenesis of this disease.
In  this  study  we  examined  the  expression  of
1,25(OH)2D3 and its possible involvement in the increased
Th1 and Th17 response as already reported previously. Our
results  showed  that  a  down-regulated  expression  of
1,25(OH)2D3 was present in active VKH patients and was
possibly one of factors responsible for the increased Th1 and
Th17 response in this disease.
METHODS
Patients and controls: A total 25 adult patients with VKH
disease (13 men and 12 women) with an average age of 38.4
years and a total 16 healthy individuals (9 men and 7 women)
with an average age of 40.5 years were included in the study.
All patients were diagnosed as having definite VKH disease
according to the diagnostic criteria revised for VKH disease
in an international committee on nomenclature [31]. Fifteen
patients  showed  active  intraocular  inflammation  (active
uveitis stage), as evidenced by mutton fat keratic precipitates,
cells in the anterior chamber and sunset glow fundus. The
systemic  findings  included  headache  (54%),  poliosis  and
alopecia (72%), vitiligo (23%), and tinnitus (46%). Ten active
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673patients were at their first attack with disease duration <6
months, and 5 active patients showed recurrent intraocular
inflammation with the duration of <2 years. Ten inactive VKH
patients  showed  typical  bilateral  sunset  glow  fundus  but
without any intraocular inflammation (inactive uveitis stage),
with the disease duration from 1 to 3 years. No systemic
corticosteroids or other immunosuppressive agents were used
at least for 2 weeks before being referred to our hospital and
blood sampling in active VKH patients. Ten patients without
active intraocular inflammation for at least 3 months after the
treatment  of  corticosteroid  and  immunosuppressant  were
chosen  as  controls.  No  patients  had  received  any  dietary
supplements before study entry. Blood samples were obtained
from these active or inactive patients during November 1,
2009 to March 31, 2010, and the daily sun exposure time was
estimated  to  be  <1.5  h  for  all  subjects.  This  study  was
approved  by  the  Ethics  Committee  of  the  First  Affiliated
Hospital  of  Chongqing  Medical  University,  and  complied
with the tenets of the Declaration of Helsinki.
1,25(OH)2D3 assays: Blood samples were collected from 8
active VKH patients, 7 inactive VKH patients and 8 healthy
controls. Serum was obtained by centrifugation at 3,000× g
for  10  min  and  stored  at  −70  °C  until  analysis.  Serum
1,25(OH)2D3  level  was  measured  using  a  commercially
available  ELISA  kit  (Immunodiagnostik,  Bensheim,
Germany) according to manufacturer’s instructions. An assay
sensitivity level was 6.0 pg/ml.
Cell  isolation  and  culture:  Anticoagulated  blood  samples
were obtained from 11 active VKH patients, 7 inactive VKH
patients  and  12  healthy  controls.  peripheral  blood
mononuclear  cells  (PBMCs)  were  isolated  using  Ficoll-
Hypaque density gradient centrifugation. Peripheral cluster of
differentiation (CD) 4+ T cells were purified by human (h)
CD4 microbeads according to the manufacturer’s instructions
(Miltenyi Biotec, Palo Alto, CA). Cells were resuspended at
1×106 cells/ml in medium RPMI 1640 (Gibco, Invitrogen,
Carlsbad, CA) containing L-glutamine (2 mM), penicillin/
streptomycin (100 U/ml), and 10% fetal calf serum. Cells were
cultured  with  or  without  1,25(OH)2D3  (Sigma-Aldrich,  St
louis,  MO)  in  37  °C,  100%  humidity,  5%  CO2  for
measurement of cell proliferation and cytokines.
Proliferation  assay:  For  proliferation  assay,  PBMCs  and
CD4+ T cells suspension was transferred to a 96-well plate
(200 μl/well), treated with or without 1,25(OH)2D3 (1×10−7
mol/l) and cultured for 5 days. Proliferation was measured
using  the  Cell  Counting  Kit  (CCK)-8  (Sigma-Aldrich,  St
louis, MO) assay, which is based on the conversion of water-
soluble  tetrazolium  salt,  WST-8  [2-(2-methoxy-4-
nitrophenyl) −3-(4-nitrophenyl)-5-(2,4-disulfophenyl) −2H-
tetrazolium, monosodium salt] to a water-soluble formazan
dye upon reduction in the presence of an electron carrier by
dehydrogenases [32]. The culture was performed in a 96-well
plate in 200 μl of medium containing 20 μl CCK-8 for 3h at
37 °C. The OD was read at 450 nm using a multi-plate reader
(SpectraMax M2e; Molecular Devices, Sunnyvale, CA).
Cytokine analysis: For determination of interleukin (IL)-17
and interferon (IFN)-γ production, PBMCs and CD4+ T cells
were  stimulated  with  or  without  anti-CD3  (monoclonal
antibody,  5μg/ml)  and  anti-CD28  antibodies  (1μg/ml;
eBioscience, San Diego, CA) for 72 h at a concentration of
1×106 cells/ml. Supernatants were collected and the levels of
IL-17  and  IFN-γ  were  measured  using  the  human  IL-17
DuoSet ELISA development kit and human IFN-γ DuoSet
ELISA development kit (R&D Systems, Minneapolis, MN)
with a detection limit of 15.6 pg/ml.
Statistics:  One-way  ANOVA,  paired-sample  t-test  were
applied using SPSS 12.0. Data were expressed as mean±SD.
A level of p<0.05 was considered to be statistically significant.
RESULTS
1,25(OH)2D3 expression in the serum of VKH patients and
controls: 1,25(OH)2D3 could be detected in the serum from
both VKH patients and controls. The level of 1,25(OH)2D3 in
active  VKH  patients  (36.3±12.7pg/ml)  was  significantly
lower than that in inactive VKH patients (57.3±8.00 pg/ml,
p=0.038) and normal controls (69.1±21.21 pg/ml, p=0.001;
Figure  1).  There  was  no  significant  difference  between
inactive VKH patients and controls concerning the serum
level of 1,25(OH)2D3.
Effect of 1,25(OH)2D3 on proliferation of PBMCs and CD4+
T cells: A primary experiment with different concentrations
of  1,25(OH)2D3  showed  that  it  significantly  inhibited  the
proliferation  of  PBMCs  from  active  VKH  patients  and
controls. Furthermore, the result showed that its inhibitory
effect  was  in  a  dose-dependent  manner  (Figure  2B).  As
1×10−7  mol/l  of  1,25(OH)2D3  could  induce  a  significant
suppression on the proliferation of PBMCs, this concentration
was used in the following experiments. Both PBMCs and
CD4+ T cells from active VKH patients showed a significantly
higher cell proliferation as compared with the inactive VKH
patients and controls. 1,25(OH)2D3 significantly inhibited the
cell proliferation of PBMCs and CD4+ T cells from all VKH
patients and controls (Figure 2C). There was no difference
among these tested three groups concerning the inhibitory
percentage.
Effect of 1,25(OH)2D3 on the production of IL-17: PBMCs and
CD4+ T cells from VKH patients and controls cultured with
1,25(OH)2D3  in  the  presence  of  anti-CD3  and  anti-CD28
antibodies were used to evaluate the influence of this molecule
on IL-17 production. A significantly increased production of
IL-17 was observed in active VKH patients as compared with
inactive  VKH  patients  (PBMCs:  p=0.039;  CD4+  T  cells:
p=0.015)  and  controls  (PBMCs:  p=0.001;  CD4+  T  cells:
p=0.002). 1,25(OH)2D3 significantly inhibited the production
of IL-17 by PBMCs and CD4+ T cells from the VKH patients
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the tested three groups concerning the inhibitory percentage.
Effect of 1,25(OH)2D3 on the production of IFN-γ: PBMCs
and CD4+ T cells from VKH patients and controls cultured
with 1,25(OH)2D3 in the presence of anti-CD3 and anti-CD28
antibodies were used to examine the influence of this molecule
on the production of IFN-γ. IFN-γ production by both PBMCs
and CD4+ T was significantly higher in active VKH patients
as compared with inactive VKH patients (PBMCs: p=0.001,
CD4+  T  cells:  p=0.018)  and  normal  controls  (PBMCs:
p=0.008, CD4+ T cells: p=0.005). 1,25(OH)2D3 significantly
down-regulated  the  production  of  IFN-γ  by  PBMCs  and
CD4+ T cells from VKH patients and controls (Figure 4A,B).
Similar  to  the  IL-17  result,  no  difference  was  found
concerning the inhibitory percentage of 1,25(OH)2D3 on the
production of IFN-γ by PBMCs and CD4+ T cells among the
tested three groups.
DISCUSSION
In this study, we showed that serum level of 1,25(OH)2D3 was
significantly decreased in the serum of active VKH patients.
1,25(OH)2D3 was able to inhibit cell proliferation of PBMCs
and CD4+ T cells. It also down-regulated the IL-17 and IFN-
γ production by activated PBMCs and CD4+ T cells from both
VKH patients and controls. These results suggested that the
decreased expression of 1,25(OH)2D3 may be involved in the
development of VKH disease.
Vitamin D is a member of the steroid thyroid superfamily
of nuclear receptors. The immune regulatory effects observed
in other autoimmune diseases stimulated us to investigate
whether 1,25(OH)2D3 was involved in the pathogenesis of
VKH  disease.  For  this  purpose,  we  first  detected  the
1,25(OH)2D3 level in the serum of VKH patients. Our results
showed that the serum level of 1,25(OH)2D3 was significantly
decreased in active VKH patients. This result is generally
consistent with those reported in other autoimmune diseases,
such as multiple sclerosis [16,17], rheumatoid arthritis [19],
and systemic lupus erythematosus [23,24]. This result suggest
that downregulated expression of 1,25(OH)2D3 was associated
with the active intraocular inflammation in VKH patients.
The decreased expression of 1,25(OH)2D3 in active VKH
diseases, but not in inactive VKH patients, suggests that it may
be  involved  in  the  pathogenesis  of  the  intraocular
inflammation in this disease. As T cell proliferation is one of
important  factors  in  the  immune  response  or  in  the
inflammation,  we  further  investigated  the  effect  of
1,25(OH)2D3 on cell proliferation. Our results showed that
1,25(OH)2D3 significantly inhibited the cell proliferation of
PBMCs and CD4+ T cells from all VKH patients and controls.
These results suggest that PBMCs and CD4+ T cells from
VKH patients and controls are similar in the sensitivity to it
with respect to cell proliferation. Our result is consistent with
early report, in which 1,25(OH)2D3 was found to suppress cell
proliferation of PBMCs or CD4+ cells in both human and
animal models [19,24,33].
As  IL-17  is  found  to  have  an  important  role  in
autoimmune  diseases  including  VKH  disease,  we  further
examined the effect of 1,25(OH)2D3 on the secretion of IL-17.
Consistent  with  our  previous  study  [34],  a  significantly
increased production of IL-17 was observed in active VKH
patients. 1,25(OH)2D3 significantly inhibited the production
of IL-17 by PBMCs and CD4+ T cells from VKH patients and
controls. These results demonstrated an inhibitory effect of
1,25(OH)2D3  on  IL-17  production  reported  in  other
autoimmune diseases [19,24,33]. Unexpectedly, we failed to
find any difference regarding the inhibitory percentage of
Figure  1.  1,25(OH)2D3  in  the  serum
from  active  VHK  patients  (n=8),
inactive VHK patients (n=7) and normal
controls (n=8).
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675Figure 2. Effect of 1,25(OH)2D3 on the
cell proliferation of PBMCs and CD4+
T cells from VKH patients and controls.
A: Cell proliferation of PBMCs from
active VKH patients (n=6) and normal
controls  (n=6)  stimulated  with
1,25(OH)2D3  of  different
concentrations. B: Cell proliferation of
PBMCs  from  active  VHK  patients
(n=11),  inactive  VHK  patients  (n=7)
and normal controls (n=12) stimulated
with  or  without  1,25(OH)2D3
(1×10−7mol/l). C: Cell proliferations of
CD4+ T cells from active VHK patients
(n=7), inactive VHK patients (n=7) and
normal controls (n=9) stimulated with
or without 1,25(OH)2D3 (1×10−7mol/l).
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6761,25(OH)2D3 on the IL-17 production among the tested three
groups, suggesting that the sensitivity of PBMCs and CD4+ T
cells  to  1,25(OH)2D3  is  not  different  concerning  IL-17
production.
Upregulated Th1 response has been found as one of the
mechanisms of autoimmune diseases including VKH disease
[34-36]. Our study further examined whether 1,25(OH)2D3
could influence the expression of IFN-γ, a typical cytokine of
Th1 cells, in VKH patients. The result showed a significantly
increased IFN-γ production by PBMCs and CD4+ T cells in
active VKH patients. This result is consistent with the results
reported  previously  [34].  Our  study  also  showed  that
1,25(OH)2D3 was able to inhibit the production of IFN-γ by
PBMCs  and  CD4+  T  cells  from  both  VKH  patients  and
controls.  Therefore,  the  sensitivity  of  both  PBMCs  and
CD4+ T cell to 1,25(OH)2D3 were not different among the
tested three groups concerning IFN-γ production.
In  summary,  our  study  revealed  that  decreased
1,25(OH)2D3  level  was  associated  with  active  intraocular
inflammation  in  VKH  patients.  1,25(OH)2D3  could
significantly inhibit cell proliferation of PBMCs and CD4+ T
cells, and down-regulated expression of IL-17 and IFN-γ.
These  results  suggest  that  down-regulated  expression  of
1,25(OH)2D3 may be one of mechanisms for the increased
IL-17 and IFN-γ in the development of VKH disease. Our
study  also  suggests  that  upregulating  1,25(OH)2D3  might
provide a new strategy for the treatment of VKH disease.
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